Bitew Molalegne, Ravishankar Chintu, Chakravarti Soumendu, Kumar Sharma Gaurav, Nandi Sukdeb
Ethiopian Biotechnology Institute (EBTI), Ethiopia.
Virus Laboratory, Center for Animal Disease Research and Diagnosis (CADRD), ICAR-Indian Veterinary Research Institute (IVRI), Izatnagar, Uttar Pradesh 243122, India.
Vet Med Int. 2019 Dec 2;2019:8762780. doi: 10.1155/2019/8762780. eCollection 2019.
Recent invasion of multiple bluetongue virus serotypes (BTV) in different regions of the world necessitates urgent development of efficient vaccine that is directed against multiple BTV serotypes. In this experimental study, cell mediated immune response and protective efficacy of binary ethylenimine (BEI) inactivated Montanide ISA 206 adjuvanted pentavalent (BTV-1, 2, 10, 16 and 23) vaccine was evaluated in sheep and direct challenge with homologous BTV serotypes in their respective group. Significant ( < 0.05) up-regulation of mRNA transcripts of IFN-, IL-2, IL-6, IL-12, IFN- and TNF- in PBMCs of vaccinated animals as compared to control (un-vaccinated) animals at certain time points was observed. On the other hand, there was a significant increase in mean ± SD percentage of CD8 T cells after 7 days post challenge (DPC) but, the mean ± SD percentage of CD4 T-cell population slightly declined at 7 DPC and enhanced after 14 DPC. Significant differences ( < 0.05) of CD8 and CD4T cells population was also observed between vaccinated and unvaccinated sheep. The vaccine also significantly ( < 0.05) reduced BTV RNA load in PBMCs of vaccinated animals than unvaccinated animals following challenge. There were no significant difference ( > 0.05) in cytokine induction, BTV RNA load and CD8 and CD4cell count among BTV-1, 2, 10, 16 and 23 serotype challenges except significant increase in mean ± SD percentage of CD8 in BTV-2 group. These findings put forwarded that binary ethylenimine inactivated montanide adjuvanted pentavalent bluetongue vaccine has stimulated cell mediated immune response and most importantly reduced the severity of BTV-1, 2, 10, 16 and 23 infections following challenge in respective group.
近期多种蓝舌病病毒血清型（BTV）侵入世界不同地区，因此迫切需要研发针对多种BTV血清型的高效疫苗。在本实验研究中，对绵羊评估了用二元乙撑亚胺（BEI）灭活并佐以Montanide ISA 206的五价（BTV-1、2、10、16和23）疫苗的细胞介导免疫反应和保护效力，并在各自组中用同源BTV血清型进行直接攻毒。在某些时间点观察到，与对照（未接种）动物相比，接种疫苗动物的外周血单核细胞（PBMC）中IFN-、IL-2、IL-6、IL-12、IFN-和TNF-的mRNA转录本显著（<0.05）上调。另一方面，攻毒后7天（DPC）CD8 T细胞的平均±标准差百分比显著增加，但CD4 T细胞群体的平均±标准差百分比在7 DPC时略有下降，在14 DPC后增加。在接种和未接种绵羊之间也观察到CD8和CD4 T细胞群体的显著差异（<0.05）。攻毒后，该疫苗还显著（<0.05）降低了接种疫苗动物PBMC中的BTV RNA载量，相比未接种疫苗的动物。在BTV-1、2、10、16和23血清型攻毒之间，细胞因子诱导、BTV RNA载量以及CD8和CD4细胞计数没有显著差异（>0.05），除了BTV-2组中CD8的平均±标准差百分比显著增加。这些发现表明，二元乙撑亚胺灭活并佐以Montanide的五价蓝舌病疫苗刺激了细胞介导的免疫反应，最重要的是，在各自组攻毒后降低了BTV-1、2、10、16和23感染的严重程度。
